Please check your internet connection and try again.
## Overview
Potassium chloride (KCl) is an electrolyte replacement used to treat or prevent hypokalemia.
## Primary Indications
* Treatment and prevention of hypokalemia.
## Adult Dosing
* **Prevention of hypokalemia:** 20 mEq (1.5 g) daily.
* **Treatment of hypokalemia:** 40-100 mEq (3-7.5 g) daily, divided into 2-5 doses.
* **Maximum dose:** Typically not to exceed 20 mEq per dose or 200 mEq (15 g) per 24 hours, depending on route and clinical status. Oral administration is preferred. IV administration is reserved for severe cases or when oral intake is impossible and requires cardiac monitoring.
## Pediatric Dosing
* **Prevention of hypokalemia:** 1-2 mEq/kg/day, maximum 100 mEq/day.
* **Treatment of hypokalemia:** 2-5 mEq/kg/day, maximum 200 mEq/day, divided into 2-5 doses.
* **Concentration limits:** For IV administration, concentrations should generally not exceed 40 mEq/L to avoid vein irritation. Higher concentrations may be used in central lines with appropriate monitoring. Exact concentrations and infusion rates should follow institutional protocols.
## Dose Adjustments
* Dose should be adjusted based on serum potassium levels and clinical assessment.
* Reduce dose in patients with renal impairment.
## Contraindications
* Severe renal impairment with oliguria, anuria, or azotemia.
* Adrenal insufficiency.
* Conditions causing elevated serum potassium levels (e.g., untreated Addison's disease, crush syndrome, severe burns, extensive tissue injury).
* Certain gastrointestinal conditions (e.g., esophageal compression, delayed gastric emptying, intestinal obstruction, peptic ulceration) when using solid oral dosage forms.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal pain, diarrhea, flatulence.
* **Serious:** Hyperkalemia (muscle weakness, fatigue, paresthesia, cardiac arrhythmias, cardiac arrest), gastrointestinal bleeding, perforation, or obstruction (especially with solid oral forms).
## Key Drug Interactions
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride), ACE inhibitors, ARBs, NSAIDs, cyclosporine, tacrolimus:** Increased risk of hyperkalemia.
* **Salt substitutes:** Often contain potassium chloride, increasing risk of hyperkalemia.
## Monitoring
* Serum potassium levels, at baseline and regularly during therapy.
* Renal function (BUN, creatinine).
* ECG, especially with rapid IV administration or in patients with cardiac disease.
* Signs and symptoms of hyperkalemia and hypokalemia.
## Clinical Pearls
* Oral formulations should be taken with meals or a full glass of water to minimize gastrointestinal irritation.
* Swallow sustained-release tablets whole; do not crush or chew.
* Rapid intravenous administration can be fatal due to hyperkalemia and cardiac arrest.
* Dosing requirements can vary significantly based on the cause and severity of potassium deficiency. Always refer to current institutional guidelines or prescribing information.
***
*Disclaimer: This information is for educational purposes only and does not substitute for professional medical advice. Always verify current prescribing information and consult with a qualified healthcare provider before making any decisions about medication.*
